BTN3A1 and neoplasm: Agonistic antibodies targeting BTN3A1 that can mimic the conformational changes that occur upon binding of pAgs have been shown to restore αβ T‐cell anti‐tumour activity while simultaneously inducing γδ T‐cell‐mediated cytotoxicity.36